Zavegepant Intranasal Spray for the Acute Treatment of Episodic Cluster Headache

Inclusion Criteria: * A diagnosis of episodic cluster headache according to the International Classification of Headache Disorders 3rd edition * A history of at least 2 prior headache bouts * Onset of cluster headache before age 50 years * Cluster headache attacks last a minimum duration of 45 minutes (if untreated) * Evidence of signed informed consent (ICF) as described in the protocol, indicating compliance with the requirements and restrictions listed in the ICF and this protocol Exclusion Criteria: General exclusions * Pregnant or breastfeeding patients. * Inability to follow training instructions for use of nasal device. * Unable to speak or read English. * Unable to access the internet (for the Questionnaires / Case Report Forms). * Females of childbearing potential, without the ability to use 2 acceptable methods of contraception to avoid pregnancy for up to 48 hours after each study drug administration, followed by 1 acceptable method for 28 days after the last administration of study treatment. * Body mass index ≥ 35 kg/m2 * Prisoners or subjects who are involuntarily incarcerated. * Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness. * Have participated in another clinical research study with biological investigational agents (or other relevant agents) in the last 90 days. * Positive drug screen for drugs of abuse at the investigator's discretion (e.g., positive amphetamines may be allowed…